Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy

• DOI: 10.1007/s12328-021-01521-4
• Publication Date: 2021-10-30T16:02:37Z
• Authors: Yalda Dehghan; Gabriel T. Schnickel; Mojgan Hosseini; Adam M. Burgoyne; Veeral H. Ajmera; Gerald P. Morris; Michel H. Mendler; Justin R. Parekh; Farid Abushamat; Irine Vodkin; Yuko Kono
• Keywords: Liver Cancer; Graft Rejection; Immune regulation; Carcinoma, Hepatocellular; Chronic Liver Disease and Cirrhosis; 610; Case Report; 03 medical and health sciences; Rare Diseases; 0302 clinical medicine; Humans; Cancer; Transplantation; Liver transplantation; 5.2 Cellular and gene therapies; Hepatology; Liver Disease; Carcinoma; Liver Neoplasms; Evaluation of treatments and therapeutic interventions; Malignancy; Hepatocellular; Organ Transplantation; 3. Good health; Infectious Diseases; Good Health and Well Being; Nivolumab; Acute rejection; Development of treatments and therapeutic interventions; Digestive Diseases; 6.4 Surgery

AbstractImmune checkpoint inhibitors (ICI) have been used to treat hepatocellular carcinoma (HCC) since 2017. The safety of ICIs in the setting of solid organ transplantation remains controversial. When used in the post-transplant setting, ICIs have been associated with high allograft rejection rates, but there are few published reports on the use of ICIs prior to transplant. We present the first reported case of rescue liver re-transplantation after loss of the first allograft due to severe acute rejection with extensive hepatic necrosis in the setting of pre-transplant ICI therapy with the PD-1 inhibitor nivolumab. It is likely that the durable immune response triggered by nivolumab contributes to graft rejection, therefore extreme caution should be taken when using ICIs before transplant until further investigation has been conducted on their safety in the pre-transplant setting.